Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2020 Oct 1;180(10):1306-1314.
doi: 10.1001/jamainternmed.2020.3134.

Effect of Sustained-Release Morphine for Refractory Breathlessness in Chronic Obstructive Pulmonary Disease on Health Status: A Randomized Clinical Trial

Cornelia A Verberkt  1 , Marieke H J van den Beuken-van Everdingen  2 , Jos M G A Schols  1   3 , Niels Hameleers  1 , Emiel F M Wouters  4   5   6 , Daisy J A Janssen  1   4
Affiliations
Randomized Controlled Trial

Effect of Sustained-Release Morphine for Refractory Breathlessness in Chronic Obstructive Pulmonary Disease on Health Status: A Randomized Clinical Trial

Cornelia A Verberkt et al. JAMA Intern Med. .

Abstract

Importance: Morphine is used as palliative treatment of chronic breathlessness in patients with advanced chronic obstructive pulmonary disease (COPD). Evidence on respiratory adverse effects and health status is scarce and conflicting.

Objective: To assess the effects of regular, low-dose, oral sustained-release morphine on disease-specific health status (COPD Assessment Test; CAT), respiratory outcomes, and breathlessness in patients with COPD.

Interventions: Participants were randomly assigned to 10 mg of regular, oral sustained-release morphine or placebo twice daily for 4 weeks, with the possibility to increase to 3 times daily after 1 or 2 weeks.

Design, setting, and participants: The Morphine for Treatment of Dyspnea in Patients With COPD (MORDYC) study was a randomized, double-blind, and placebo-controlled study of a 4-week intervention. Patients were enrolled between November 1, 2016, and January 24, 2019. Participants were recruited in a pulmonary rehabilitation center and 2 general hospitals after completion of a pulmonary rehabilitation program. Outpatients with COPD and moderate to very severe chronic breathlessness (modified Medical Research Council [mMRC] breathlessness grades 2-4) despite optimal pharmacological and nonpharmacological treatment were included. A total of 1380 patients were screened, 916 were ineligible, and 340 declined to participate.

Main outcomes and measures: Primary outcomes were CAT score (higher scores represent worse health status) and arterial partial pressure of carbon dioxide (Paco2). Secondary outcome was breathlessness in the previous 24 hours (numeric rating scale). Data were analyzed by intention to treat. Subgroup analyses in participants with mMRC grades 3 to 4 were performed.

Results: A total of 111 of 124 included participants were analyzed (mean [SD] age, 65.4 [8.0] years; 60 men [54%]). Difference in CAT score was 2.18 points lower in the morphine group (95% CI, -4.14 to -0.22 points; P = .03). Difference in Paco2 was 1.19 mm Hg higher in the morphine group (95% CI, -2.70 to 5.07 mm Hg; P = .55). Breathlessness remained unchanged. Worst breathlessness improved in participants with mMRC grades 3 to 4 (1.33 points lower in the morphine group; 95% CI, -2.50 to -0.16 points; P = .03). Five participants of 54 in the morphine group (9%) and 1 participant of 57 in the placebo group (2%) withdrew because of adverse effects. No morphine-related hospital admissions or deaths occurred.

Conclusions and relevance: In this randomized clinical trial, regular, low-dose, oral sustained-release morphine for 4 weeks improved disease-specific health status in patients with COPD without affecting Paco2 or causing serious adverse effects. The worst breathlessness improved in participants with mMRC grades 3 to 4. A larger randomized clinical trial with longer follow-up in patients with mMRC grades 3 to 4 is warranted.

Trial registration: ClinicalTrials.gov Identifier: NCT02429050.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Janssen reported receiving personal fees from Boehringer Ingelheim, personal fees from Novartis, and personal fees from AstraZeneca outside the submitted work. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Study Design
T indicates time.
Figure 2.
Figure 2.. Flowchart of the Morphine for Treatment of Dyspnea in Patients With COPD (MORDYC) Study
COPD indicates chronic obstructive pulmonary disease; mMRC, modified Medical Research Council.
See this image and copyright information in PMC

Comment in

References

    1. Janssen DJ, Spruit MA, Uszko-Lencer NH, Schols JM, Wouters EF. Symptoms, comorbidities, and health care in advanced chronic obstructive pulmonary disease or chronic heart failure. J Palliat Med. 2011;14(6):735-743. doi:10.1089/jpm.2010.0479 - DOI - PubMed
    1. Agusti A, Calverley PMA, Celli B, et al. ; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators . Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res. 2010;11(1):122. doi:10.1186/1465-9921-11-122 - DOI - PMC - PubMed
    1. Curtis JR, Patrick DL. The assessment of health status among patients with COPD. Eur Respir J Suppl. 2003;41(41):36s-45s. doi:10.1183/09031936.03.00078102 - DOI - PubMed
    1. Johnson MJ, Yorke J, Hansen-Flaschen J, et al. . Towards an expert consensus to delineate a clinical syndrome of chronic breathlessness. Eur Respir J. 2017;49(5):1602277. doi:10.1183/13993003.02277-2016 - DOI - PubMed
    1. Celli BR, Cote CG, Marin JM, et al. . The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(10):1005-1012. doi:10.1056/NEJMoa021322 - DOI - PubMed

Publication types

Associated data